Insight into the Development of PET Radiopharmaceuticals for Oncology

Insight into the Development of PET Radiopharmaceuticals for Oncology

While the development of positron emission tomography (PET) radiopharmaceuticals closely follows that of traditional drug development, there are several key considerations in the chemical and radiochemical synthesis, preclinical assessment, and clinical translation of PET radiotracers. As such, we o...

Full description

Bibliographic Details
Main Authors: Joseph Lau, Etienne Rousseau, Daniel Kwon, Kuo-Shyan Lin, François Bénard, Xiaoyuan Chen
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
positron emission tomography
diagnostic imaging
radiopharmaceuticals
radiochemistry
personalized medicine
Online Access:https://www.mdpi.com/2072-6694/12/5/1312

Similar Items

Similar Items